Company intelligence / Profile preview
Diakonos Oncology
Houston, Texas, United Statesdiakonosoncology.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Phase 1 trial for GBM showed 88% 12-month survival rate compared to 53% historical survival with standard of care. 12 of 16 newly diagnosed GBM patients remained alive with no serious adverse events attributable to DOC1021 at an average of 12.9 months follow-up. The company has received Fast Track and Orphan Drug designations from the FDA for GBM and Fast Track designation for pancreatic cancer.[10][9]
- Therapeutic areas
- Oncology
- Modalities
- Dendritic Cell Vaccines (DCVs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Diakonos Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diakonos Oncology.